In patients with non-small cell lung cancer, certain comorbidities impact survival
the ONA take:
According to a new study published in the journal Lung, researchers have found that certain comorbidities in patients with non-small cell lung cancer (NSCLC) significantly negatively impact survival. For the study, researchers sought to investigate the negative prognostic factor of individual comorbidities in patients with primary lung cancer. They identified 10,378 patients who were diagnosed with NSCLC between 2009 and 2011. Results showed that patients with NSCLC and cardiovascular comorbidity have a 30% increased mortality rate (HR = 1.30; 95% CI: 1.13 - 1.49) compared with those without comorbidity. In addition, patients with diabetes (HR = 1.19; 95% CI: 1.02 - 1.39), cerebrovascular disorders (HR = 1.18; 95% CI: 1.05 - 1.33), and chronic obstructive pulmonary disease (COPD) (HR = 1.20; 95% CI: 1.10 - 1.39) have an approximately 20% increased mortality rate compared with those without comorbidity.
Primary lung cancer is one of the most frequently occurring types of cancer, and morbidity has been shown to negatively impact survival in patients with lung cancer. This study shows that comorbid cardiovascular disease, diabetes, cerebrovascular disorders, and COPD individually increase the death rate of patients by 20% to 30%.
A family member serves as a caregiver for a patient with cancer.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Study Reveals Relationship of Sleep Duration, Diabetes Risk in Cancer Survivors
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|